FESC MD - NewAmsterdam Pharma Chief Founder

NAMS Stock   21.77  0.99  4.76%   

Insider

FESC MD is Chief Founder of NewAmsterdam Pharma
Age 68
Phone31 35 206 2971
Webhttps://www.newamsterdampharma.com

NewAmsterdam Pharma Management Efficiency

The company has return on total asset (ROA) of (0.2927) % which means that it has lost $0.2927 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4737) %, meaning that it created substantial loss on money invested by shareholders. NewAmsterdam Pharma's management efficiency ratios could be used to measure how well NewAmsterdam Pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

INSIDER Age

Noel MBAPepGen
55
Hennie HoogenboomMerus BV
N/A
Andy MeyerJanux Therapeutics
41
Filip MDMonte Rosa Therapeutics
51
LLM JDRezolute
63
Sharon TownsonMonte Rosa Therapeutics
50
Jennifer CormierPepGen
N/A
Frederic CrenInventiva Sa
59
James McArthurPepGen
63
Sonia DPHILPepGen
38
Jeff KnightCrinetics Pharmaceuticals
54
Seth LewisMolecular Partners AG
N/A
Silvia BuonamiciMonte Rosa Therapeutics
N/A
Niels SvenstrupPepGen
55
Rex CFAAnebulo Pharmaceuticals
64
Corinne SavillCullinan Oncology LLC
66
Vered MBACompass Therapeutics
54
Sven MDMerus BV
62
Steve AndreCullinan Oncology LLC
N/A
Joseph BolenPureTech Health PLC
70
Kerry WhalenCullinan Oncology LLC
N/A
NewAmsterdam Pharma (NAMS) is traded on NASDAQ Exchange in USA. It is located in Gooimeer 2-35, Naarden, Netherlands, 1411 DC and employs 62 people. NewAmsterdam Pharma is listed under Biotechnology category by Fama And French industry classification.

Management Performance

NewAmsterdam Pharma Leadership Team

Elected by the shareholders, the NewAmsterdam Pharma's board of directors comprises two types of representatives: NewAmsterdam Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NewAmsterdam. The board's role is to monitor NewAmsterdam Pharma's management team and ensure that shareholders' interests are well served. NewAmsterdam Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NewAmsterdam Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Louise Kooij, Treasurer, CFO
Jim Jacobson, Chief Secretary
Annie Neild, VP Affairs
FESC MD, Chief Founder
Marc MD, Chief Officer
MSc MBA, Chief Officer
Lina Gugucheva, Chief Officer
Sheng Cui, Chief Officer
Douglas Kling, Chief Officer
FACC Facp, President CEO
Bob Rambo, Executive Marketing
MBA Jones, Chief Officer
FACC Facc, President, CEO
Mayur Somaiya, Chief Officer
Matthew Philippe, Executive Relations

NewAmsterdam Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NewAmsterdam Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.